Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lannett Company, a manufacturer of generic pharmaceutical products, has received approvals from the FDA of its abbreviated new drug applications for doxycycline tablets, 75mg and 150mg, the generic equivalent of Adoxa marketed by Par Pharmaceutical.
Subscribe to our email newsletter
Doxycycline is indicated for the treatment of bacterial infections, such as urinary tract infections, acne, gonorrhea, chlamydia, periodontitis and others.
Arthur Bedrosian, president and CEO of Lannett, said: “The approvals of doxycycline tablets, 75mg and 150mg, round out our doxycycline portfolio, supplementing our 50mg and 100mg dosages. We will commence marketing our doxycycline tablets, 75mg and 150mg, immediately.”